Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study

Journal of Translational Medicine

Kamal Amin²  Tejal Gandhi²  Morton Brown¹  Wei Wei¹  Powel Kazanjian² 

[1] Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA;Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA

关键词: AIDS;    HAART;    CD4;    Viral Load;   

Others  :  1208476
DOI  :  10.1186/1479-5876-3-40

 received in 2005-07-12, accepted in 2005-10-31,  发布年份 2005

【 摘 要 】

Background

A sizeable number of HIV-infected patients receiving HAART do not maintain prolonged virologic suppression. We evaluated long-term HIV viral load (VL) responses to HAART as a risk factor for AIDS events (AE) that is independent of CD4 responses.

Methods

A cohort of patients with pre-therapy CD4 < 200/mm³ who had CD4 and VL measurements for > one year after receiving HAART at a university clinic were prospectively enrolled. Cox proportional multivariate regression model was used to determine whether CD4 and VL responses were independently associated with new AE.

Results

The patient (N = 214) mean baseline CD4 = 92/mm³, VL = 219,000 c/mL and follow-up duration 42.3 months (range 13–72 months). A new AE occurred in 56 patients; CD4 cell count response to HAART that remained < 200/mm³ throughout the study period was a significant risk factor for new AE (RR = 9.7–12.5; p < 0.001). Similarly, VL responses that remained > 5,000 c/mL during this period was also a significant risk factor (RR = 6.7–12.8; p = 0.001) that was independent of CD4 response adjusted for <> 200/mm³.

Conclusion

Maintaining adequate long-term virologic responses to HAART provides a clinical benefit independent of CD4 responses.

【 授权许可】

   
2005 Kazanjian et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Palella F, Delaney K, Moorman A: Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998, 338:853-60.
• [2]Ledergerber B, Egger B, Erard V, et al.: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA 1999, 282:2220-6.
• [3]Ferrer E, Santamarina E, Santin M, et al.: Progression to AIDS/Death is higher in patients initiating ARV with CD4 counts < 350 [abstract]. 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA 2003, 910.
• [4]Van Sighem AI, van de Wiel MA, Ghani A, on behalf of the ATHENA cohort study group, et al.: Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003, 17:2227-36.
• [5]Egger M, May M, Chene G, ART Cohort Collaboration, et al.: Prognosis of HIV-1 Infected patients starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies. Lancet 2002, 360:119-29.
• [6]Sterling TR, Chaisson RE, Keruly J, et al.: Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy among Human Immunodeficiency Virus-Infected Patients who Achieve Durable Virologic Suppression: Longer Follow-Up of an Observational Cohort Study. J Infect Dis 2003, 188:1659-65.
• [7]Tierney C, Lathey JL, Christopherson C, et al.: Prognostic value of baseline HIB type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003, 187:144-8.
• [8]Wood E, Hogg R, Yip B, et al.: Higher baseline levels of plasma HIV type 1 RNA are associated with increased mortality after initiation of triple drug antiretroviral therapy. J Infect Dis 2003, 188:1421-5.
• [9]de Wolfe R, Spijkerman I, Schellekens P: AIDS prognosis based on HIV-1 RNA, CD4+ T cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799-806.
• [10]Tarwater PM, Gallant JE, Mellors JW, et al.: Prognostic value of plasma HIV RNA among highly active antiretroviral users. AIDS 2004, 18:2419-23.
• [11]Raffanti SP, Fusco JS, Sherrill BH, et al.: Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. J Acquir Immune Defic Syndr 2004, 37:1147-54.
• [12]ART Cohort Collaboration: Prognostic importance of initial response in HIV-1 infected patients starting patent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362:679-86.
• [13]Kaplan JE, Hanson DL, Jones JL, et al.: Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001, 15:1831-36.
• [14]Olsen CH, Gatel J, Ledergerber B, et al.: Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005, 19:319-30.
• [15]Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-68.
• [16]Belec L, Piketty C, Si-Mohammed A, et al.: High levels of drug resistant HIV in patients exhibiting increasing CD4 T cell counts despite virologic failure of protease inhibitor-containing ARV. J Inf Dis 2000, 181:1808-12.
• [17]Kaufmann G, Furrer H, Perrin L, et al.: Low Baseline CD4 T-cell Count and Higher Age Predict Poor CD4 T-cell Recovery in Treated HIV-1 Infected Individuals Suppressing HIV-1 RNA to Levels <1000 copies/mL for 5 Years [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; SF, CA 2004, 557.
• [18]Department of Health and Human Services [DHHS] Guidelines [http://www.aidsinfo.nih.gov] webcite
• [19]Centers for Disease Control and Prevention: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992, 41(RR-17):1-19.
• [20]Deeks SG, Hecht FM, Swanson M, et al.: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
• [21]King MS, Bernstein BM, Walmsley SL, et al.: Baseline HIV-1 RNA level and CD4 count predict time to loss of virologic response to nelfinavir but not lopinavir/ritonavir in antiretroviral therapy-naïve patients. J Inf Dis 2004, 190:280-4.
• [22]Ribaudo H, Downey G, Fischl M, et al.: Factors Associated with Virologic Failure and Their Impact on Treatment Outcomes: An Analysis of Virologic Failure in ACTG 388 [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; SF, CA 2004, 553.
• [23]Paredes R, Mocroft A, Kirk O, et al.: Predictors of virologic success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Arch Intern Med 2000, 160:1123-32.
• [24]Mocroft A, Ledergerber B, Viard JP, et al.: Time to Triple Drug Class Failure after Initiation of HAART [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; SF, CA 2004, 554.
• [25]van Leth F, Andrews S, Grinsztjen B, et al.: Virologic Failure in Antiretroviral Therapy Naive Patients Is Only Determined by Extreme Low Values of CD4+ Cells or High Values of HIV-1 RNA Concentration, Not by Choice of Treatment with Nevirapine or Efavirenz [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; SF, CA 2004, 550.
• [26]PLATO Collaboration: Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with biological failure to all three antiretroviral drug classes. Lancet 2004, 364:51-62.
• [27]Kuritzkes DR: Effect of Antiretroviral Resistance on Response to Treatment-Experienced Patients. The AIDS Reader 2003, 13:S5-11.
• [28]Schwarcz S, Hsu L: AIDS in the HAART Era: the Extent and Characteristics of Late HIV Testers [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; SF, CA 2004, 864.
• [29]Nash D, Manning SE, Ramaswamy C: Descriptive Epidemiology of HIV/AIDS in New York City: Incorporation of Newly Available Population-based Surveillance Data on HIV (non-AIDS), 2001 [abstract]. 11th Conference on Retroviruses and Opportunistic Infections; SF, CA 2004, 87.
• [30]Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report. 1998, 9:28.
• [31]Moorman AC, Von Bargen JC, Palella FJ, et al.: Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:182-8.
• [32]Mocroft A, Lederberger B, Katlama C, EuroSIDA study group, et al.: Decline in AIDS and Death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-39.
• [33]Ives N, Gazzard BG, Easterbrook PJ: Changing pattern of AIDS defining illnesses with introduction of Highly active antiretroviral therapy in a London clinic. J Infect 2001, 42:134-9.
• [34]Sabin C, D'Arminio Monforte A, May M, et al.: The Changing incidence of Clinical AIDS events in 12,574 treatment naive patients starting HAART [abstract]. 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA 2003, 569.
• [35]Yeni PG, Hammer SM, Hirsch MS, et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004, 292:251-65.